Drug intelligence / Profile preview

carboplatin + olaparib + paclitaxel

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of carboplatin (a platinum-based chemotherapy), olaparib (a PARP inhibitor), and paclitaxel (a taxane chemotherapy). This regimen works through multiple mechanisms: carboplatin induces DNA cross-linking, olaparib inhibits DNA repair by blocking PARP1/2, and paclitaxel prevents microtubule formation during cell division. The combination has shown synergistic effects in cancer treatment, particularly for ovarian cancer and other advanced solid tumors.

Brand names: LynparzaParaplatinTaxol
Other names: olaparib plus weekly carboplatin and paclitaxel

Targets

TUBB (Tubulin (alpha and beta subunits))DNAPARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on carboplatin + olaparib + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + olaparib + paclitaxel.

Explore the full profile